Skip to main content
Medpace Holdings, Inc. logo

Medpace Holdings, Inc. — Investor Relations & Filings

Ticker · MEDP ISIN · US58506Q1094 LEI · 549300H8TYEUVTW14A54 US Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2024-04-29 Regulatory Filings
Country US United States of America
Listing US MEDP

About Medpace Holdings, Inc.

https://investor.medpace.com/

Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization (CRO) that provides Phase I-IV clinical development services. The company serves the biotechnology, pharmaceutical, and medical device industries, with a mission to accelerate the development of safe and effective medical therapeutics. Medpace employs a disciplined operating approach that leverages regulatory and therapeutic expertise. Its services include clinical pharmacology, central laboratory, bioanalytical, ECG core lab, and imaging core labs. The company has expertise across major therapeutic areas, including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective diseases.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-04-29 English
10-Q
Interim / Quarterly Report Q1 2024
2024-04-23 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 22, 2024, by Medpace Holdings, Inc. It announces the issuance of a press release containing financial results for the quarter ended March 31, 2024. The text explicitly states that the press release is furnished as an exhibit and posted on the company's website. The document itself does not contain detailed financial statements or substantive financial data but rather serves as a current report announcing the earnings release. According to the classification rules, an initial announcement of quarterly financial results in a press release format corresponds to an Earnings Release (ER). The document length is 4022 characters, which is consistent with a short announcement rather than a full report. Therefore, the correct classification is Earnings Release (ER).
2024-04-22 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed with the SEC. It is labeled as 'Definitive Additional Materials' related to a proxy statement. Proxy statements and related materials are classified under Proxy Solicitation & Information Statement (PSI). The document length is short (1270 characters) and it contains no financial data or report content, confirming it is proxy solicitation material rather than a financial report or other filing type.
2024-04-03 English
DEF 14A
Proxy Solicitation & Information Statement
2024-04-03 English
ARS
Annual Report
2024-04-03 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.